The ERCC1 C118T Polymorphism Predicts Clinical Outcomes of Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Meta-analysis Based on 22 Studies

Background: Although the predictive value of the excision repair cross-complementing group 1 (ERCC1)C118T polymorphism in clinical outcomes of patients with colorectal cancer (CRC) receiving oxaliplatin-basedchemotherapy has been evaluated in numerous published studies, the conclusions are conflicting. Therefore, weperformed the present meta-analysis to determine the precise role of the ERCC1 C118T polymorphism in thisclinical situation and help optimize individual chemotherapy. Materials and Methods: A multiple search strategywas used to identify eligible studies. Pooled odds ratios (ORs) and their 95% confidence intervals (CIs) wereused to estimate objective response and oxaliplatin-induced toxicity, with hazard ratios (HRs) with 95%CIs forprogression-free survival (PFS) and overall survival (OS). Results: A total of 22 studies including 2,846 CRCpatients were eligible in the analysis. Overall, no significant correlation was found between the ERCC1 C118Tpolymorphism and objective response to oxaliplatin-based chemotherapy, in all patients or in the Asian andCaucasian subgroups. However, the pooled analysis showed that the PFS and OS were significantly shorter inpatients who carried T/T or T/C genotypes of ERCC1 C118T as compared to the C/C genotype. On stratifiedanalysis by ethnicity, the ERCC1 118T allele was associated with a favorable prognosis in Caucasians (PFS,HR=0.58, 95%CI: 0.24-1.44; OS, HR=0.38, 95%CI: 0.22-0.64) but an unfavorable prognosis in Asians (PFS,HR=2.49, 95%CI: 1.87-3.33; OS, HR=2.63, 95%CI: 1.87-3.69) based on a dominant model. In addition, wefailed to find a statistically significant impact of ERCC1 C118T polymorphism on oxaliplatin-induced toxicity.Conclusions: The ERCC1 C118T polymorphism may have prognostic value in patients with CRC undergoingoxaliplatin-based chemotherapy.     

XPD Lys751Gln and Asp312Asn Polymorphisms and Gastric Cancer Susceptibility: A Meta-analysis of Case-control Studies

Background: Published data regarding the association between xeroderma pigmentosum group D (XPD)Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility havew been inconclusive. Thismeta-analysis was therefore performed toobtain a more precise estimation of any relationship. Materials andMethods: A comprehensive literature search was conducted to identify all case–control studies of Lys751Glnand Asp312Asn polymorphisms and susceptibility to gastric cancer. Summary odds ratios (ORs) and its95% confidence intervals (95% CIs) were calculated using a random-effects model with the software STATA(version10.0). Results: A total of 12 case-control studies including 3,147 cases and 4,736 controls were included.Overall, no significant associations were found in some models (for Lys751Gln: Lys/Gln vs Lys/Lys: OR=1.144,95% CI=0.851–1.541, Gln/Gln vs Lys/Lys: OR=1.215, 95% CI = 0.740–1.955, dominant model: OR=1.137,95% CI=0.818–1.582; recessive model: OR=1.123, 95% CI=0.765–1.650; for Asp312Asn: Asp/Asn vs Asp/Asp:OR=1.180, 95% CI=0.646–2.154, dominant model: OR=1.380, 95% CI = 0.812–2.346), but significantly elevatedsusceptibility was found for Asp312Asn polymorphism in some models (Asn/Asn vs Asp/Asp: OR=2.045, 95%CI=1.254–3.335, recessive model: OR=1.805, 95% CI =1.219–2.672 ), for the additive model, the XPD Lys751Glnand Asp312Asn polymorphisms were not significantly associated with gastric cancer susceptibility. In stratifiedanalyses, significantly elevated susceptibility was found for some models in the Chinese population. Conclusion:This meta-analysis suggested the XPD Asp312Asn polymorphism might be a potential biomarker of gastriccancer susceptibility in overall population, while both XPD Lys751Gln and Asp312Asn polymorphisms mightbe risk factors of gastric cancer susceptibility in Chinese.     

Association Between Polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln Genes and Prognosis of Colorectal Cancer in a Chinese Population

We conducted this study to detect associations between XRCC1 Arg399Gln and XPD Lys751Gln genotypesand survival of colorectal cancer patients treated with 5-FU/oxalipatin chemotherapy. We included 289 Chinesepatients with advanced colorectal cancer, who had received 5-FU/oxalipatin chemotherapy as first-line treatmentfrom January 2005 to January 2007. All patients were followed up till Nov. 2011. Genotyping for XRCC1Arg399Gln and XPD Lys751Gln polymorphisms was based upon duplex polymerase-chain-reaction with thePCR-RFLP method. In our study, we found the XRCC1 399 Gln/Gln genotype to confer significantly higherrates of response to chemotherapy when compared to the Arg/Arg genotype [OR (95% CI)= 2.56(1.57-2.55)].patients with the XPD 751 Gln/Gln genotype had significantly higher rates of response to chemotherapy [OR(95% CI)= 1.54(0.87-2.65)] and those with the XRCC1 399 Gln/Gln genotype had a longer average survivaltime and significantly lower risk of death than did those with the Arg/Arg genotype [HR (95% CI)= 0.66(0.36-0.95)]. Similarly, those carrying the XPD 751Gln/Gln genotype had 0.51-fold the risk of death of those with XPD751Lys/Lys [HR (95% CI)= 0.51(0.33 -0.94)]. In conclusion, it is suggested that the XRCC1 Arg399Gln and XPDLys751Gln polymorphisms should be routinely assessed to determine colorectal patients who are more likely tobenefit from 5-FU/oxalipatin chemotherapy.     

XPD Lys751Gln and Asp312Asn Polymorphisms and Susceptibility to Skin Cancer: A Meta-Analysis of 17 Casecontrol Studies

Background: Numerous studies have explored the influence of XPD Lys751Gln and/or Asp312Asn polymorphisms on skin cancer susceptibility. However, the results remain inconclusive. To derive a more precise estimation, we conducted a comprehensive search to identify all available published studies and performed a meta-analysis. Materials and Methods: Electronic literature searches of the PubMed, CBM and CNKI databases were performed up to March 2014. Odds ratios (ORs) with 95% confidence intervals (CIs) were applied to assess the strength of associations. Results: Seventeen case-control studies were included with a total sample size of 6, 113 cases and 11, 074 controls for the XPD Lys751Gln polymorphism, and 10 studies (3, 840cases and 7, 637 controls) for the XPD Asp312Asn polymorphism were pooled for analysis. Overall, no significantassociations were found between the XPD Lys751Gln polymorphism and skin cancer risk in any genetic model. On stratified analysis by tumor type, XPD Lys751Gln polymorphism was not associated with increased risk of non-melanoma skin cancer, but was significantly related with increased risk of cutaneous melanoma (Gln/Gln vs Lys/Lys: OR=1.15, 95%CI=1.02-1.29, p=0.023; dominant model: OR=1.09, 95%CI=1.01-1.18, p=0.036). For the XPD Asp312Asn polymorphism, no significant association with skin cancer risk was observed in overall or subgroup analyses. Conclusions: The present meta-analysis suggests that the XPD Lys751Gln polymorphism may contribute to the risk of cutaneous melanoma from currently available evidence. Further investigations are needed to obtain more insight into possible roles of these two polymorphisms in skin carcinogenesis.     

TP53 Arg72Pro and XPD Lys751Gln Gene Polymorphisms and Risk of Lung Cancer in Bangladeshi Patients

Background: Tumor suppressor gene (TP53) is considered as the most frequently mutated gene in almost all forms of human cancer. Moreover, genetic variations in the XPD gene affect the DNA repair capacity increasing cancer susceptibility. Polymorphisms within these genes can play a major role in determining individual lung cancer susceptibility. However, several studies have investigated this possibility; but reported conflicting results. Therefore, the objective of this study was to investigate the role of TP53 Arg72Pro and XPD Lys751Gln gene polymorphisms on lung cancer susceptibility in the Bangladeshi population. Materials and Methods: Study subjects comprised of 180 lung cancer patients and 200 healthy volunteers. Genetic polymorphism of TP53 was determined by multiplex PCR-based method, while XPD genotypes were analyzed using Polymerase Chain Reaction-based Restriction Fragment Length Polymorphism (PCR-RFLP) method. Lung cancer risk was estimated as odds ratio (OR) and 95% confidence interval (CI). Results: From the results, no significant association between TP53 Arg72Pro polymorphism and lung cancer risk was observed. Whereas, patients with homozygous mutant variants (Gln/Gln) of XPD at codon 751 were found significantly associated with lung cancer risk when compared to the control (OR=3.58; 95% CI=1.58-8.09; p=0.002). Lung cancer risk was found significantly higher with Gln/Gln variants of XPD among smokers (OR=4.03; 95% CI=1.11-14.63; p=0.026). Significant increased risk of lung cancer was found with Arg/Pro genotypes of TP53, Lys/Gln and Gln/Gln variants of XPD in individuals with family history of cancer (OR=3.44; 95% CI=1.36-8.72; p=0.011; OR=3.17; 95% CI=1.20-8.39; p=0.024; OR=16.35; 95% CI=0.92-289.5; p=0.007, respectively). Conclusion: The findings indicated that homozygous mutant variants (Gln/Gln) of XPD were associated with increased lung cancer risk, whereas TP53 Arg72Pro polymorphism was not associated with risk of lung cancer among Bangladeshi patients.     

DNA修复基因XPD751单核苷酸多态性与 结直肠癌化疗疗效的相关性

 目的 研究结直肠癌患者DNA修复基因XPD751单核苷酸多态性与铂类药物化疗敏感度的关系。方法 经病理学确诊的晚期结直肠癌患者98例,均行草酸铂联合5-氟尿嘧啶的方案（FOLFOX）治疗。所有病例化疗前抽取静脉血并提取DNA,采用多聚酶链反应 限制性片段长度多态性分析（PCR RFLP）技术检测XPD751单核苷酸多态性。比较不同基因型与化疗疗效的关系。结果 （1）XPD751 Lys/Lys、Lys/Gln和Gln/Gln基因型频度分别为76（77.55%）、17（17.35%）和5（5.10%）。（2）XPD751 Lys/Lys、Lys/Gln 和Gln/Gln基因型有效率分别为50.00%、29.41%和20%,比较Lys/Lys、Lys/Gln的有效率,两者之间的差异有统计学意义（χ²=4.04,P<0.05）。在调整性别、年龄及不同转移部位的影响后,XPD751 Lys/Gln基因型患者化疗失败的可能性是Lys/Lys 基因型患者的3.8倍,OR=3.8,95%CI为0.985~14.698。结论 DNA修复基因XPD751单核苷酸多态性与结直肠癌对FOLFOX方案化疗敏感度相关,检测XPD751单核苷酸多态性可能成为预测结直肠癌患者接受FOLFOX方案化疗敏感度的指标。     

贝伐单抗联合化疗一线治疗转移性结直肠癌的Meta分析

目的 评价贝伐单抗（bevacizumab,BEV)联合化疗一线治疗转移性结直肠癌（metastaticcolorectal cancer, mCRC）的有效性和安全性。方法 通过The Cochrane Library、PubMed、EMBASE和中国生物医学文献数据库（CBM）、中国期刊全文数据库（CNKI）、维普数据库（VIP）、万方数据库等检索有关BEV联合化疗一线治疗mCRC的随机对照试验（randomized control trial, RCT）;主要研究指标是无进展生存时间（progression free survival, PFS）和总生存时间（overall survival,OS）,次要研究指标包括有效率（objective response rate, ORR）和不良反应;采用相对危险度（relative risk, RR）和风险比（hazard ratios, HR）为效应量,各效应量以95%置信区间（95%CI）表示,Stata 11.0统计软件进行Meta分析。结果 共纳入9项RCT,共3 930例mCRC患者,Meta分析结果显示,与单纯化疗相比,贝伐单抗(bevacizumb, BEV)联合化疗可以降低疾病进展风险（HR=0.62,P<0.0001, 95%CI: 0.64~0.74）和疾病死亡风险（HR=0.84, P<0.001,95%CI: 0.73~0.95）,提高mCRC的ORR（RR=0.80, P<0.001,95%CI: 0.60~0.93）。亚组分析显示BEV联合双药方案可降低疾病进展风险（HR=0.68, P<0.001, 95%CI: 0.46~0.89）,但并没有降低疾病死亡风险（HR=0.85, P=0.068,95%CI:0.68~1.03）;BEV联合氟尿嘧啶类单药降低疾病进展风险（HR=0.56,P<0.001, 95%CI: 0.47~0.64）和疾病死亡风险（HR=0.83,P<0.001,95%CI:0.68~0.97）。在不良反应方面,B E V 联合化疗没有增加治疗相关死亡率（RR=0.97, P=0.91,95%CI:0.62~1.54）;增加BEV相关不良反应发生率。结论 BEV联合化疗一线治疗能提高mCRC患者PFS、OS和RR。BEV联合不同化疗方案所带来生存获益大小不同。虽然BEV相关不良反应增加,但是可控的。     

Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy

Polymorphisms in DNA repair genes were thought to represent important determinants of platinum drug efficacy. This study tested whether XPD Lys751Gln and XRCC1 T-77C polymorphisms were associated with survival in platinum-treated patients with advanced non-small-cell lung cancer (NSCLC). In this study, 199 advanced NSCLC patients with platinum-based chemotherapy were recruited. During the median 26.5 months of follow-up, patients with the XPD 751Lys/Lys genotype had a median survival time of 17.0 months (95% CI, 14.5-19.6 months), not much longer than those carried Lys/Gln heterozygote (12.0 months; 95% CI, 3.4-20.6 months; log-rank test, P = 0.542). In Cox proportional hazards model, no significant associations were found between XPD Lys751Gln polymorphism and survival. For XRCC1 T-77C polymorphism, the median survival of patients with TC + CC genotype (18 months; 95% CI, 13.5-22.5 months) was similar to those with the TT genotype (16.0 months; 95% CI, 13.3-18.7 months; log-rank test, P = 0.399). XRCC1 T-77C polymorphism was not associated with survival in Cox proportional hazards model. Additionally, the analysis for combination of these two polymorphisms also showed no prognostic significance for NSCLC. Our findings indicated that neither XPD Lys751Gln nor XRCC1 T-77C could be genetic determinant for prognosis of advanced NSCLC patients treated with platinum-based chemotherapy.     

Neutrophil-related Variables Have Different Prognostic Effect Based on Primary Tumor Location in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy

BackgroundClinical data reported a relationship between neutrophil-related variables and poor prognosis in patients with metastatic colorectal cancer (mCRC), but only platelet-to-lymphocyte ratio has been reported as prognostic.Patients and MethodsA retrospective analysis of 145 patients with mCRC, who received chemotherapy at the department of Oncology of the Ospedale Civile di Sanremo in 2010 to 2013, was performed, and a Cox model was built.ResultsIn the model, some variables were independently related with overall survival (OS) (resection of the primary tumor, number of drugs included in the first-line chemotherapy regimen), whereas neutrophil-related ones were not. However, after stratification by tumor location, neutrophil-related variables appeared associated with a poor survival among patients with a left-sided mCRC, and in particular, among those ones with a rectal tumor (hazard ratio, 3.732; 95% confidence interval, 1.575-8.845).ConclusionNeutrophil-related variables predicted outcome in patients with left-sided mCRC only. A high prevalence of consensus molecular subtype 4 CRC in patients with metastatic cancer of the rectum is suggested.     

Prognostic Value of NRAS Gene for Survival of Colorectal Cancer Patients: A Systematic Review and Meta-Analysis

Introduction: NRAS gene is associated with malignant proliferation and metastasis of colorectal cancer (CRC).But its prognostic value on CRC is still unknown. The objective of this study is to perform a meta-analysis to obtainits prognostic value on survival of CRC patients. Methods: The systematic review and meta-analysis was designed,undertaken and reported using items from the PRISMA statement. Relevant articles were identified through PubMed(containing Medline), Embase, Web of Science databases and Google scholar search engines from their inception up toOctober 3, 2016. The articles about NRAS on prognosis of CRC patients were enrolled. The association between NRASand CRC survival time (including overall survival [OS], progression-free survival [PFS], and disease-free survival[DFS]) was evaluated using hazard ratio (HR) with its corresponding 95% confidence interval (CI). Results: A totalof fifteen articles were included. High-expression of NRAS was significantly associated with poor OS (HR: 1.36, 95%CI: 1.15–1.61), and poor PFS (HR: 1.75, 95% CI: 1.04–2.94). The combined HR of NRAS on DFS was 0.87 (95% CI:0.37–2.03). Subgroup analysis showed that NRAS was significantly associated with poor OS for patients from Westerncountries (HR: 1.38, 95% CI: 1.09–1.73), but not for those from Asian countries. Conclusions: This meta-analysisdemonstrate that NRAS gene could predict the poor prognosis for the CRC patients. More large-sample cohort studiesare needed to further confirm this conclusion.     

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Prostate Cancer: a Systematic Review with Meta-analysis

Background: The vascular endothelial growth factor (VEGF) mediates vasculogenesis and angiogenesisthrough promoting endothelial cell growth, migration and mitosis, and has involvement in cancer pathogenesis,progression and metastasis. However, the prognostic value of VEGF in patients with prostate cancer remainscontroversial. Objectives: The aim of our study was to evaluate the prognostic value of VEGF in prostate cancer,and summarise the results of related research on VEGF. Methods: In accordance with an established searchstrategy, 11 studies with 1,529 patients were included in our meta-analysis. The correlation of VEGF-expressionwith overall survival and progression-free survival was evaluated by hazard ratio, either given or calculated.Results: The studies were categorized by introduction of the author, demographic data in each study, prostatecancer-relatived information, VEGF cut-off value, VEGF subtype, methods of hazard ratio (HR) estimationand its 95% confidence interval (CI). High VEGF-expression in prostate cancer is a poor prognostic factor withstatistical significance for OS (HR=2.32, 95%CI: 1.40–3.24). However, high VEGF-expression showed no effecton poor PFS (HR=1.30, 95%CI: 0.88–1.72). Using Begg’s, Egger’s test and funnel plots, we confirmed lack ofpublication bias in our analysis. Conclusion: VEGF might be regarded as a prognostic maker for prostate cancer,as supported by our meta-analysis. To achieve a more definitive conclusion enabling the clinical use of VEGF inprostate cancer, we need more high-quality interventional original studies following agreed research approachesor standards.     

The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk

We evaluated the association between the XPD exon 10 Asp(312)Asn and exon 23 Lys(751)Gln polymorphisms and the risk of pancreatic cancer in a hospital-based study of 344 patients and 386 controls frequency matched by age, gender, and race. Stratified analyses showed ever smokers carrying the Asn(312)Asn genotype had a significantly reduced risk when compared with those carrying the (312)Asp allele (OR=0.46, 95% confidence interval 0.24-0.88) (P for interaction=0.03). The (312)Asp-(751)Gln was identified as the putative at risk haplotype. Our study shows that the XPD gene polymorphism could be a genetic risk modifier for smoking-related pancreatic cancer.     

Prognostic Significance of Beclin-1 Expression in Colorectal Cancer: a Meta-analysis

Objective: Beclin-1 has recently been observed as an essential marker of autophagy in several cancers.However, the prognostic role of Beclin-1 in colorectal neoplasia remains controversial. Our study aimed toevaluate the potential association between Beclin-1 expression and the outcome of colorectal cancer patients.Materials and Methods: All related studies were systematically searched in Pubmed, Embase, Springer andChinese National Knowledge Infrastructure databases (CNKI), and then a meta-analysis was performed todetermine the association of Beclin-1 expression with clinical outcomes. Finally, a total of 6 articles were includedin our analysis. Results: Our data showed that high Beclin-1 expression in patients with CRC was associatedwith poor prognosis in terms of tumor distant metastasis (OR=2.090, 95%CI=1.061-4.119, p=0.033) and overallsurvival (RR=1.422, 95%CI=1.032-1.959, p=0.031). However, we did not found any correlation between Beclin-1over-expression and tumor differentiation (OR=1.711, 95%CI=0.920-3.183, p=0.090). In addition, there was noevidence of publication bias as suggested by Egger’s tests for tumor distant metastasis (p=1.000), differentiation(p=1.000) and OS (p=0.308). Conclusions: Our present meta-analysis indicated that elevated Beclin-1 expressioniss associated with tumor metastasis and a poor prognosis in patients with CRC. Beclin-1 might serve as anefficient prognostic indicator in CRC, and could be a new molecular target in CRC therapy.     

Association Between XPD Asp312Asn Polymorphism and Esophageal Cancer Susceptibility: A Meta-analysis

Objective: To investigate the association between xeroderma pigmentosum group D (XPD) Asp312Asnpolymorphism and esophageal cancer (EC) susceptibility by meta-analysis. Methods: We searched PubMed up toApril 9th, 2012, to identify relevant papers, and 8 published case-control studies including 2165 EC patients and3141 healthy controls were yielded. Odds ratios (ORs) with relevant 95% confidence intervals (CIs) were appliedto assess the association between XPD Asp312Asn polymorphism and EC susceptibility with the ComprehensiveMeta-Analysis software, version 2.2. Results: Overall, the meta-analysis results suggested the XPD Asp312Asnpolymorphism to be significantly associated with EC susceptibility [(Asn/Asn+Asp/Asn) vs. Asp/Asp: OR=1.20,95%CI=1.05-1.36, p=0.01; and Asp/Asn vs. Asp/Asp: OR= 1.15, 95%CI =1.01-1.31, p=0.04]. In the subgroupanalysis by ethnicity and cancer type, significantly associations were found for Caucasian populations [(Asn/Asn+Asp/Asn) vs. Asp/Asp: OR=1.26, 95%CI =1.08-1.47, p<0.001; Asp/Asn vs. Asp/Asp: OR=1.19, 95%CI =1.02-1.40, p=0.03] and esophageal squamous cell carcinoma [(Asn/Asn+Asp/Asn) vs. Asp/Asp: OR=1.19, 95%CI=1.01-1.41, p=0.04]. There was no heterogeneity and no publication bias existed. Conclusions: This meta-analysisshows that the XPD Asp312Asn polymorphism may be a risk factor for developing EC, especially for Caucasianpopulations and esophageal squamous cell carcinoma.     

Prognostic Value of C-Reactive Protein in Esophageal Cancer: a Meta-analysis

Background: The classical inflammatory biomarker, C-reactive protein (CRP), has been identified to be relatedto progression of esophageal cancer. Some research showed that elevated pretreatment serum CRP indicated apoor prognosis, but results have been inconsistent. Materials and Methods: We searched the Medline, Embaseand the Cochrane Central Search Library for suitable studies and a meta–analysis of eleven (1,886 patients) wasconducted to examine the relationship between elevated serum CRP level and overall survival (OS) in esophagealcancer cases. Moreover, correlation analyses were conducted to assess links between pretreatment serum CRPlevel and tumor node metastasis (TNM) stage as well as T, N, M grade, respectively. Results: The pooled analysisshowed that elevated pretreatment serum CRP level was significantly associated with poorer overall survival (HR2.09, 95%CI 1.52-2.87, p<0.01). Subgroup analyses were conducted by “country”, “cut-off value”, “treatment”and “number of patients”, and no single factor could alter the result. Elevated pretreatment serum CRP wassignificantly correlated with more advanced TNM stage and T, N, M grade respectively. Conclusions: Elevatedpretreatment serum CRP levels are associated with poorer prognosis in esophageal cancer patients, and couldserve as a useful biomarker for outcome prediction.     

The Exonuclease 1 Glu589Lys Gene Polymorphism and Cancer Susceptibility: Evidence Based on a Meta-analysis

Background: Published studies on the association between the exonuclease 1 (EXO1) Glu589Lys polymorphismand cancer susceptibility have yielded conflicting results. Thus, a meta-analysis of published studies was performedto assess the possible association. Materials and Methods: All eligible case-control studies published up to January2013 on the association between the EXO1 Glu589Lys polymorphism and cancer susceptibility were identified bysearching PubMed, Web of Science, Science Direct and hand search. Either fixed-effect or random-effect modelswere used to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs) using the ComprehensiveMeta-Analysis software version 2.2. Results: A total of 4,391 cancer cases and 4,339 controls from 10 studieswere included. Overall, no significant association between the EXO1 Glu589Lys polymorphism and cancersusceptibility was observed in either genetic model. However; in subgroup analyses by cancer type, a significantassociation between EXO1 Glu589Lys and lung cancer risk was found (Lys vs Glu: OR=1.23, 95%CI=1.07-1.41, pheterogeneity=0.05). Further, subgroup analysis by ethnicity indicated that there was a statistically increasedcancer risk in Asians (Lys vs Glu: OR=1.42, 95%CI=1.30-1.55, pheterogeneity=0.07; Lys/Lys vs Glu/Glu: OR=1.93,95%CI=1.20-3.12, pheterogeneity=0.01; Lys/Lys+Glu/Lys vs Glu/Glu: OR=1.52, 95%CI=1.37-1.68, pheterogeneity=0.42;Lys/Lys vs Glu/Lys+Glu/Glu: OR=1.68, 95%CI=1.07-2.65, pheterogeneity=0.02). However, significant association wasabsent in Caucasians. Conclusions: This meta-analysis suggests, for the first time, that the EXO1 Glu589Lyspolymorphism is not associated with overall cancer susceptibility, although marginal associations were found forlung cancer and Asian subgroups. Additional well-designed studies with larger sample size focusing on differentethnicities and cancer types are needed to confirm these findings.     

Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer

Purpose

To evaluate a prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer (mCRC).

Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy

Aim: There is increasing evidence that ERCC1 and XPD have roles in response to chemotherapy amongpatients with NSCLC, but the results are conflicting. Therefore, we conducted the present prospective study ina Chinese population. Methods: A total of 632 primary NSCLC patients were included, followed-up from May2006 to May 2011. Polymorphisms were detected by real time PCR with TaqMan probse, using genomic DNAextracted from peripheral blood samples. The Cox regression model was used to analyze the hazard ratios (HR)for ERCC1 and XPD. Results: The median time of follow-up was 31.6 months. Our results showed the ERCC1118 T/T(HR=1.65, 95% CI=1.17-2.43) and XPD 751 Gln/ Gln genotypes (HR=1.52, 95%CI=1.04-2.08) wereassociated with an increased risk of death from NSCLC. Moreover, the ERCC118 T allele and XPD 751 Glnallele genotypes had a more higher risk of death from NSCLC among both ex-smokers and current smokers.Conclusion: In summary, ERCC1 and XPD gene polymorphisms might provide better prognostic predictiveinformation for NSCLC patients in Chinese populations, with smoking possibly interacting with the genotypes.